Taysha

October 2, 2025

Taysha Receives FDA Breakthrough Therapy Designation for TSHA-102

August 12, 2025

Taysha Advances REVEAL Pivotal Trial for Rett Syndrome

Ben Deverman, PhD | Senior Director of Vector Engineering at the Broad Institute of MIT and Harvard

How Will Cuts to FDA and NIH Impact Gene Therapy Clinical Trials and Rett Syndrome Research?

rsrt-news-jan25-genetherapyupdate-hdr

January 15, 2025

A Review of Gene Therapy Clinical Trials

November 13, 2024

Taysha Releases Financial, Enrollment Update and Community Letter

August 12, 2024

Taysha Rett Program Updates Q2 2024

Taysha Announced New Clinical Data from the REVEAL Phase 1/2 Adolescent & Pediatric Trial Evaluating TSHA-102

Taysha Rett Program Updates March 2024

February 29, 2024

Taysha Provides Updates for all their Clinical Trials (CAN, US, UK)

Gene Therapy for Rett Highlights 2023

January 16, 2024

A Concise Summary of Gene Therapy Clinical Trials for Rett Syndrome

First Pediatric Patient Dosed in Taysha US Clinical Trial

January 10, 2024

First Pediatric Patient Dosed in Taysha US Clinical Trial

Taysha Gene Therapies reports on safety and efficacy results for the first patient to receive gene therapy for Rett Syndrome

December 27, 2023

Taysha Pediatric Gene Therapy Trial Is Open for Enrollment in US

Taysha Gene Therapies reports on safety and efficacy results for the first patient to receive gene therapy for Rett Syndrome

November 29, 2023

Taysha Expands Age Eligibility for Canadian Clinical Trial

news_article_-_taysha_1

Taysha Cleared to Dose Second Patient in Gene Therapy Trial

news_article_-_taysha_1

Taysha Gene Therapies Doses First Rett Syndrome Patient

hero-taysha-gene-therapies-shares-letter-to-the-rett-syndrome-community-1

February 1, 2023

Taysha Provides Update For Their Rett Syndrome Gene Replacement Program

mini-mecp2-banner

January 10, 2023

The Story Behind Mini-MeCP2

2022-accomplishments-newsbanner

December 19, 2022

What We Accomplished in 2022

Roadmap to Cures

$40M